Val66Met polymorphism association with serum BDNF and inflammatory biomarkers in major depression

Abstract Objectives: Current evidence supports participation of neurotrophic and inflammatory factors in the pathogenesis of major depressive disorder (MDD). Some studies reported an association between the Val66Met polymorphism (rs6265) of brain-derived neurotrophic factor (BDNF) gene with MDD and peripheral BDNF levels. However, no previous studies have examined the association of this polymorphism with inflammation. The present study assessed the association of the Val66Met polymorphism with serum levels of BDNF and inflammatory markers among depressed outpatients. Methods: All participants (n = 73) met DSM-IV criteria for a unipolar depressive episode. The serum levels of BDNF and inflammatory biomarkers (IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ) were compared between individuals presenting with at least one Met allele (Met-carriers) and those homozygous for the Val allele. Results: In our sample (84.9% female, mean age 52.4 ± 10.3 years), 24.7% (n = 18) were Met-carriers. After Bonferroni correction, the Met allele was significantly associated with higher BDNF and lower TNF-α. These associations persisted after adjusting for potential confounders. Conclusions: The pattern of low BDNF and high inflammation in MDD may be influenced by the Val66Met polymorphism. The association of a polymorphism in the BDNF gene with inflammatory markers in addition to BDNF levels suggests an interaction between these systems.

[1]  A. Carvalho,et al.  Peripheral cytokine and chemokine alterations in depression: a meta‐analysis of 82 studies , 2017, Acta psychiatrica Scandinavica.

[2]  M. Fava,et al.  Inflammatory cytokines in major depressive disorder: A case–control study , 2017, The Australian and New Zealand journal of psychiatry.

[3]  A. Juvekar,et al.  Agmatine ameliorates lipopolysaccharide induced depressive-like behaviour in mice by targeting the underlying inflammatory and oxido-nitrosative mediators , 2016, Pharmacology Biochemistry and Behavior.

[4]  K. Hashimoto,et al.  Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets , 2016, Current neuropharmacology.

[5]  Lingpeng Zhu,et al.  Esculetin attenuates lipopolysaccharide (LPS)-induced neuroinflammatory processes and depressive-like behavior in mice , 2016, Physiology & Behavior.

[6]  P. Ganz,et al.  Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. , 2016, Journal of affective disorders.

[7]  Andrew H. Miller,et al.  The role of inflammation in depression: from evolutionary imperative to modern treatment target , 2015, Nature Reviews Immunology.

[8]  Lin Yuan,et al.  Resveratrol abrogates lipopolysaccharide-induced depressive-like behavior, neuroinflammatory response, and CREB/BDNF signaling in mice. , 2015, European journal of pharmacology.

[9]  Y. González-Giraldo,et al.  No Association of BDNF, COMT, MAOA, SLC6A3, and SLC6A4 Genes and Depressive Symptoms in a Sample of Healthy Colombian Subjects , 2015, Depression research and treatment.

[10]  R. Pinheiro,et al.  The Met allele of BDNF Val66Met polymorphism is associated with increased BDNF levels in generalized anxiety disorder , 2015, Psychiatric genetics.

[11]  F. Balcı,et al.  TNF-alpha inhibition prevents cognitive decline and maintains hippocampal BDNF levels in the unpredictable chronic mild stress rat model of depression , 2015, Behavioural Brain Research.

[12]  Klaus P. Ebmeier,et al.  Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder , 2015, Brain, Behavior, and Immunity.

[13]  B. Penninx,et al.  Association between smoking, nicotine dependence, and BDNF Val66Met polymorphism with BDNF concentrations in serum. , 2015, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[14]  Yuko Fujita,et al.  Antidepressant Effects of TrkB Ligands on Depression-Like Behavior and Dendritic Changes in Mice After Inflammation , 2015, The international journal of neuropsychopharmacology.

[15]  M. Riva,et al.  Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity , 2014, Front. Cell. Neurosci..

[16]  T. Numakawa,et al.  The Role of Brain-Derived Neurotrophic Factor in Comorbid Depression: Possible Linkage with Steroid Hormones, Cytokines, and Nutrition , 2014, Front. Psychiatry.

[17]  G. Parker,et al.  Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure , 2014, Neuropsychiatric disease and treatment.

[18]  B. Penninx,et al.  Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484) , 2014, Molecular Psychiatry.

[19]  B. Frey,et al.  Val66Met polymorphism and serum brain‐derived neurotrophic factor in bipolar disorder: an open‐label trial , 2014, Acta psychiatrica Scandinavica.

[20]  J. Zhang,et al.  Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice , 2014, Neuroscience.

[21]  R. Duman.  Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections , 2014, Dialogues in clinical neuroscience.

[22]  B. Penninx,et al.  Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features , 2014, Brain, Behavior, and Immunity.

[23]  K. Tansey,et al.  Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis , 2014, BMC Medicine.

[24]  J. Bukh,et al.  Are variations in whole blood BDNF level associated with the BDNF Val66Met polymorphism in patients with first episode depression? , 2013, Psychiatry Research.

[25]  D. Schlessinger,et al.  Genetics of serum BDNF: Meta-analysis of the Val66Met and genome-wide association study , 2013, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[26]  H. Anisman,et al.  Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses , 2013, Front. Cell. Neurosci..

[27]  R. Ferrell,et al.  Brain-Derived Neurotrophic Factor Serum Levels and Genotype: Association with Depression during Interferon-α Treatment , 2013, Neuropsychopharmacology.

[28]  J A Bilello,et al.  Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study , 2013, Molecular Psychiatry.

[29]  T. Connor,et al.  Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression , 2013, Brain, Behavior, and Immunity.

[30]  G. Aghajanian,et al.  Synaptic Dysfunction in Depression: Potential Therapeutic Targets , 2012, Science.

[31]  H. Anisman,et al.  Inflammatory Factors Contribute to Depression and Its Comorbid Conditions , 2012, Science Signaling.

[32]  R. Ho,et al.  Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. , 2012, Journal of affective disorders.

[33]  B. Franke,et al.  Increase in Serum Brain-Derived Neurotrophic Factor in Met Allele Carriers of the BDNF Val66Met Polymorphism Is Specific to Males , 2012, Neuropsychobiology.

[34]  L. Monteggia,et al.  Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders , 2012, Pharmacological Reviews.

[35]  J. Micó,et al.  Neurotrophins Role in Depression Neurobiology: A Review of Basic and Clinical Evidence , 2011, Current neuropharmacology.

[36]  B. Penninx,et al.  Serum levels of brain-derived neurotrophic factor in major depressive disorder: state–trait issues, clinical features and pharmacological treatment , 2010, Molecular Psychiatry.

[37]  B. Penninx,et al.  The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met , 2010, Psychopharmacology.

[38]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Major Depression , 2010, Biological Psychiatry.

[39]  B. Franke,et al.  Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity , 2010, Molecular Psychiatry.

[40]  James L. McClelland,et al.  Meta‐analysis of brain‐derived neurotrophic factor p.Val66Met in adult ADHD in four European populations , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[41]  Kerang Zhang,et al.  Genetic association of the interaction between the BDNF and GSK3B genes and major depressive disorder in a Chinese population , 2010, Journal of neural transmission.

[42]  N. Akarsu,et al.  The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels , 2010, Brain Research Bulletin.

[43]  R. Yoshimura,et al.  Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[44]  J. Gallinat,et al.  The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations , 2009, Molecular Psychiatry.

[45]  D. Kozaric-Kovacic,et al.  Ethnic differences in brain-derived neurotrophic factor Val66Met polymorphism in Croatian and Korean healthy participants. , 2009, Croatian medical journal.

[46]  R. Duman,et al.  Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and Implications , 2008, Biological Psychiatry.

[47]  B. McEwen,et al.  Impact of genetic variant BDNF (Val66Met) on brain structure and function. , 2008, Novartis Foundation symposium.

[48]  J. Groves,et al.  Is it time to reassess the BDNF hypothesis of depression? , 2007, Molecular Psychiatry.

[49]  P. Deloukas,et al.  The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans , 2007, Neuroreport.

[50]  J. Flint,et al.  No association between the BDNF Val66Met polymorphism and mood status in a non-clinical community sample of 7389 older adults. , 2007, Journal of psychiatric research.

[51]  B. Frey,et al.  Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder , 2007, Molecular Psychiatry.

[52]  Jidong Fang,et al.  Peripheral immune activation by lipopolysaccharide decreases neurotrophins in the cortex and hippocampus in rats , 2006, Brain, Behavior, and Immunity.

[53]  S. Cichon,et al.  Evidence for a Relationship Between Genetic Variants at the Brain-Derived Neurotrophic Factor (BDNF) Locus and Major Depression , 2005, Biological Psychiatry.

[54]  M. Egan,et al.  The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function , 2003, Cell.

[55]  C. Antunes,et al.  Color and genomic ancestry in Brazilians , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  R. Duman,et al.  Antidepressants and neuroplasticity. , 2002, Bipolar disorders.

[57]  R. Duman,et al.  Neuronal plasticity and survival in mood disorders , 2000, Biological Psychiatry.

[58]  P. Amorim.  Mini International Neuropsychiatric Interview (MINI): validacao de entrevista breve para diagnostico de transtornos mentais , 2000 .

[59]  F. Hefti,et al.  Systemic interleukin-1β decreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation , 1993, Neuroscience.

[60]  Sati Mazumdar,et al.  Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale , 1992, Psychiatry Research.

[61]  B. Linn,et al.  CUMULATIVE ILLNESS RATING SCALE , 1968, Journal of the American Geriatrics Society.

[62]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[63]  H. Steinbusch,et al.  Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor? , 2011, The international journal of neuropsychopharmacology.

[64]  R. Shelton,et al.  Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. , 2009, Journal of psychiatric research.

[65]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..